Dongbang Medical is set to enter the Brazilian market with its PHD HA Filler.

Dongbang Medical announced in a regulatory filing on the 10th that it has obtained product approval for PHD HA Filler from Brazil's National Health Surveillance Agency (ANVISA). The approval was granted on the 9th local time.

As a result, Dongbang Medical is now able to sell PHD HA Filler, one of its products, in Brazil.

Dongbang Medical explained that November 10, the date of the decision (confirmation) stated in the filing, is the date it received the approval letter from ANVISA.